RDY vs. ABBV
Compare and contrast key facts about Dr. Reddy's Laboratories Limited (RDY) and AbbVie Inc. (ABBV).
Performance
RDY vs. ABBV - Performance Comparison
Loading graphics...
RDY vs. ABBV - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
RDY Dr. Reddy's Laboratories Limited | -4.06% | -10.53% | 14.13% | 36.47% | -19.74% | -7.33% | 76.80% | 8.45% | 0.37% | -16.46% |
ABBV AbbVie Inc. | -5.16% | 33.08% | 18.86% | -0.23% | 24.01% | 32.43% | 27.72% | 1.47% | -0.96% | 60.07% |
Fundamentals
RDY:
$11.22B
ABBV:
$381.37B
RDY:
$67.92
ABBV:
$2.38
RDY:
0.20
ABBV:
90.18
RDY:
0.03
ABBV:
6.23
RDY:
$345.83B
ABBV:
$61.16B
RDY:
$188.26B
ABBV:
$44.85B
RDY:
$93.77B
ABBV:
$28.29B
Returns By Period
In the year-to-date period, RDY achieves a -4.06% return, which is significantly higher than ABBV's -5.16% return. Over the past 10 years, RDY has underperformed ABBV with an annualized return of 4.79%, while ABBV has yielded a comparatively higher 18.93% annualized return.
RDY
- 1D
- -2.74%
- 1M
- -6.33%
- YTD
- -4.06%
- 6M
- -5.14%
- 1Y
- 3.00%
- 3Y*
- 6.72%
- 5Y*
- 2.48%
- 10Y*
- 4.79%
ABBV
- 1D
- -1.15%
- 1M
- -8.23%
- YTD
- -5.16%
- 6M
- -10.68%
- 1Y
- 7.72%
- 3Y*
- 14.56%
- 5Y*
- 19.12%
- 10Y*
- 18.93%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
RDY vs. ABBV — Risk / Return Rank
RDY
ABBV
RDY vs. ABBV - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Dr. Reddy's Laboratories Limited (RDY) and AbbVie Inc. (ABBV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| RDY | ABBV | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.13 | 0.29 | -0.16 |
Sortino ratioReturn per unit of downside risk | 0.33 | 0.56 | -0.23 |
Omega ratioGain probability vs. loss probability | 1.04 | 1.08 | -0.03 |
Calmar ratioReturn relative to maximum drawdown | 0.14 | 0.36 | -0.22 |
Martin ratioReturn relative to average drawdown | 0.25 | 0.80 | -0.55 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| RDY | ABBV | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.13 | 0.29 | -0.16 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.11 | 0.85 | -0.74 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.18 | 0.74 | -0.56 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.36 | 0.74 | -0.37 |
Correlation
The correlation between RDY and ABBV is 0.21, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
RDY vs. ABBV - Dividend Comparison
RDY's dividend yield for the trailing twelve months is around 0.68%, less than ABBV's 3.09% yield.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
RDY Dr. Reddy's Laboratories Limited | 0.68% | 0.65% | 0.60% | 1.39% | 1.48% | 1.04% | 0.46% | 0.71% | 0.00% | 0.78% | 0.62% | 0.63% |
ABBV AbbVie Inc. | 3.09% | 2.87% | 3.49% | 3.82% | 3.49% | 3.84% | 4.41% | 4.83% | 3.89% | 2.65% | 3.64% | 3.41% |
Drawdowns
RDY vs. ABBV - Drawdown Comparison
The maximum RDY drawdown since its inception was -60.62%, which is greater than ABBV's maximum drawdown of -45.09%. Use the drawdown chart below to compare losses from any high point for RDY and ABBV.
Loading graphics...
Drawdown Indicators
| RDY | ABBV | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -60.62% | -45.09% | -15.53% |
Max Drawdown (1Y)Largest decline over 1 year | -19.60% | -16.31% | -3.29% |
Max Drawdown (5Y)Largest decline over 5 years | -35.25% | -21.92% | -13.33% |
Max Drawdown (10Y)Largest decline over 10 years | -47.13% | -45.09% | -2.04% |
Current DrawdownCurrent decline from peak | -19.52% | -10.68% | -8.84% |
Average DrawdownAverage peak-to-trough decline | -21.94% | -10.70% | -11.24% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 10.96% | 7.58% | +3.38% |
Volatility
RDY vs. ABBV - Volatility Comparison
Dr. Reddy's Laboratories Limited (RDY) and AbbVie Inc. (ABBV) have volatilities of 7.69% and 7.61%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| RDY | ABBV | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 7.69% | 7.61% | +0.08% |
Volatility (6M)Calculated over the trailing 6-month period | 16.19% | 18.69% | -2.50% |
Volatility (1Y)Calculated over the trailing 1-year period | 23.81% | 27.07% | -3.26% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 22.93% | 22.62% | +0.31% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 26.44% | 25.70% | +0.74% |
Financials
RDY vs. ABBV - Financials Comparison
This section allows you to compare key financial metrics between Dr. Reddy's Laboratories Limited and AbbVie Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
RDY vs. ABBV - Profitability Comparison
RDY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Dr. Reddy's Laboratories Limited reported a gross profit of 44.23B and revenue of 87.27B. Therefore, the gross margin over that period was 50.7%.
ABBV - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, AbbVie Inc. reported a gross profit of 13.96B and revenue of 16.62B. Therefore, the gross margin over that period was 84.0%.
RDY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Dr. Reddy's Laboratories Limited reported an operating income of 14.24B and revenue of 87.27B, resulting in an operating margin of 16.3%.
ABBV - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, AbbVie Inc. reported an operating income of 5.81B and revenue of 16.62B, resulting in an operating margin of 35.0%.
RDY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Dr. Reddy's Laboratories Limited reported a net income of 12.10B and revenue of 87.27B, resulting in a net margin of 13.9%.
ABBV - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, AbbVie Inc. reported a net income of 1.82B and revenue of 16.62B, resulting in a net margin of 10.9%.